Retatrutide for PCOS: Off-Label Use, Evidence, and Dosing Protocol

What Is Retatrutide and Why Does It Matter for PCOS?

Retatrutide is an investigational single-molecule peptide that activates three receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. This triple mechanism produces greater weight loss than dual agonists like tirzepatide in head-to-head dose comparisons from phase 2 data. PCOS is the most common endocrine disorder in reproductive-age women, affecting roughly 8 to 13 percent of women globally according to the World Health Organization, and insulin resistance is present in 65 to 70 percent of affected women regardless of body weight. [1]

The overlap between obesity, hyperinsulinemia, and PCOS pathophysiology is the biological argument clinicians use when considering retatrutide off-label. It is not an approved treatment. The FDA has not reviewed a New Drug Application for retatrutide in any indication as of July 2025.

How the Triple-Agonist Mechanism Addresses PCOS Biology

GLP-1 receptor agonism reduces appetite, slows gastric emptying, and improves pancreatic beta-cell function. In women with PCOS, GLP-1 receptor agonists such as liraglutide 1.2 mg daily reduced free testosterone by a mean of 22 percent and restored ovulation in 34 percent of anovulatory participants over 12 weeks in a 2015 trial by Jensterle et al. (N=30) published in the European Journal of Endocrinology. [2]

GIP receptor agonism augments fat-cell lipolysis and adiponectin secretion. Adiponectin is consistently low in women with PCOS and inversely correlates with androgen levels. [3]

Glucagon receptor agonism increases energy expenditure at rest and promotes hepatic glucose output regulation. For PCOS, the hepatic component matters because non-alcoholic fatty liver disease affects up to 30 percent of women with PCOS, worsening insulin signaling systemically. [4]

Retatrutide Is Not Approved: The Regulatory Baseline

The FDA approved tirzepatide (Mounjaro, Zepbound) for type 2 diabetes and obesity. Semaglutide (Ozempic, Wegovy) carries approvals for the same indications plus cardiovascular risk reduction. Retatrutide has neither. Eli Lilly submitted phase 2 results in 2023 and phase 3 trials (TRIUMPH program) are ongoing as of mid-2025. Prescribing retatrutide for any patient today means prescribing a compound that has not passed the FDA's full safety and efficacy review, which carries legal, ethical, and clinical risk that must be disclosed during informed consent.

What the Phase 2 Trial Data Actually Show

The phase 2 retatrutide obesity trial (N=338, published in the New England Journal of Medicine in 2023) remains the most cited source for efficacy data. Participants received once-weekly subcutaneous injections of 1 mg, 4 mg, 8 mg, or 12 mg retatrutide or placebo for 48 weeks. [5]

Weight Reduction by Dose

Mean body-weight reductions at 48 weeks were:

• 1 mg: 8.7 percent
• 4 mg: 17.3 percent
• 8 mg: 22.8 percent
• 12 mg: 24.2 percent
• Placebo: 2.1 percent

All active doses were statistically superior to placebo (P<0.001). The 8 mg and 12 mg cohorts achieved weight reductions that exceed those reported for semaglutide 2.4 mg (14.9 percent at 68 weeks in STEP-1, N=1,961) and tirzepatide 15 mg (20.9 percent at 72 weeks in SURMOUNT-1, N=2,519). [6][7]

Metabolic Markers Relevant to PCOS

Fasting insulin dropped by a mean of 42 percent in the 8 mg cohort at 48 weeks. HOMA-IR, a surrogate for insulin resistance, fell proportionally. Waist circumference, a marker of central adiposity and androgen-driven fat distribution in PCOS, decreased by a mean of 18.4 cm in the 12 mg group. [5]

No retatrutide trial has measured androgen levels, LH-to-FSH ratios, antral follicle counts, or menstrual regularity. Those data gaps are the central limitation when extrapolating to PCOS.

The Type 2 Diabetes Phase 2 Trial

A parallel phase 2 trial in adults with type 2 diabetes (N=281) showed retatrutide 12 mg reduced HbA1c by a mean of 2.26 percentage points at 24 weeks, superior to placebo and non-inferior to dulaglutide 1.5 mg. [8] Fasting glucose fell by 68 mg/dL at the highest dose. Women with PCOS and concurrent type 2 diabetes or prediabetes may see additive benefit in glycemic control, though this remains speculative without a dedicated trial.

Off-Label Prescribing: Legal and Ethical Framework

Off-label prescribing is legal in the United States. The FDA permits physicians to prescribe approved or investigational drugs outside their labeled indications when clinical judgment supports it. However, retatrutide is not yet approved for any indication, which creates an additional layer of consideration beyond standard off-label use.

Compound Pharmacies and Compounded Retatrutide

Some compounding pharmacies have marketed retatrutide peptide preparations. These products are not FDA-reviewed for purity, potency, or sterility. The FDA issued warning letters in 2024 targeting compounders of GLP-1 receptor agonist peptides, and the same regulatory posture applies to investigational compounds. [9] A clinician prescribing compounded retatrutide for PCOS should document that the patient has received this disclosure in writing.

Informed Consent Requirements

Before prescribing, the clinician must document that the patient understands:

1. Retatrutide is not FDA-approved for any use.
2. No trial has tested it specifically in women with PCOS.
3. Long-term safety data beyond 48 weeks do not exist.
4. Reproductive safety is unknown; no animal teratogenicity studies in this specific context have been published for PCOS populations.
5. The patient should use effective contraception during treatment and for at least two months after stopping, consistent with the approach used for other GLP-1-class agents in reproductive-age women.

The Endocrine Society's 2023 obesity pharmacotherapy guidelines state: "Pharmacological treatment of obesity should be considered as an adjunct to lifestyle intervention in patients with BMI ≥30 kg/m² or BMI ≥27 kg/m² with weight-related complications." [10] PCOS with significant metabolic dysfunction qualifies as a weight-related complication under that framing, which some clinicians use to anchor the rationale.

Evidence Grade for Retatrutide in PCOS

Using the GRADE framework, the evidence for retatrutide specifically in PCOS is Very Low. The reasoning:

• No direct randomized controlled trial in women with PCOS exists.
• All mechanistic arguments rely on indirect evidence from the obesity phase 2 trial and from trials of other GLP-1 receptor agonists in PCOS.
• Risk of bias is high because extrapolation across populations introduces confounding.
• Imprecision is high: effect size on PCOS-specific outcomes (androgen levels, ovulation rate, menstrual regularity) is entirely unknown.

The American College of Obstetricians and Gynecologists (ACOG) 2023 PCOS guidance lists lifestyle modification and metformin as first-line metabolic interventions, with GLP-1 receptor agonists noted as emerging options where obesity complicates PCOS. [11] Retatrutide is not named in any current guideline.

Proposed Off-Label Dosing Protocol for PCOS (Clinician Reference)

The following protocol is extrapolated from the phase 2 titration schedule used in the Eli Lilly obesity trial. No PCOS-specific dosing study exists. This is a clinician reference framework, not a prescribing mandate.

Eligibility Criteria Before Starting

Candidates who may be considered are women with confirmed PCOS (Rotterdam criteria: two of three: oligo/anovulation, clinical or biochemical hyperandrogenism, polycystic ovaries on ultrasound) plus at least one of the following:

• BMI ≥27 kg/m² with metabolic dysfunction (HOMA-IR >2.5, dyslipidemia, or prediabetes)
• BMI ≥30 kg/m² regardless of metabolic markers
• Failure of at least six months of metformin plus lifestyle intervention
• Contraindication or intolerance to approved first-line agents

Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, active pancreatitis, pregnancy, or planned pregnancy within the treatment window. [5]

Titration Schedule

| Week | Dose | Notes | |------|------|-------| | 1 to 4 | 2 mg subcutaneous once weekly | Baseline labs at week 0 | | 5 to 8 | 4 mg subcutaneous once weekly | Assess tolerability; hold if GI grade 3+ | | 9 to 12 | 4 mg or advance to 6 mg | Advance only if <5% weight loss and tolerating well | | 13 to 24 | 6 to 8 mg subcutaneous once weekly | Target metabolic response zone | | 25 onward | 8 to 12 mg if needed | Maximum explored in phase 2 trials |

Titration should slow or pause if nausea exceeds grade 2 (CTCAE v5.0 scale) or if vomiting causes dehydration. The phase 2 trial used 4-week titration intervals; that cadence is preserved here because faster escalation increased dropout due to GI adverse events.

Monitoring Parameters

Labs at baseline, week 12, and week 24:

• Fasting glucose, fasting insulin, HOMA-IR
• Total testosterone, free testosterone, SHBG
• LH, FSH, estradiol (days 2 to 4 of cycle, or random if anovulatory)
• Lipid panel, ALT, AST (given hepatic involvement in PCOS)
• HbA1c if prediabetes or diabetes present
• Serum lipase if abdominal pain occurs at any point

Menstrual cycle regularity should be tracked using a cycle diary from baseline. Ovulation confirmation by midluteal progesterone (>3 ng/mL on day 21 or equivalent) is a reasonable secondary endpoint if fertility is the treatment goal. [12]

Combination with Metformin

Metformin 500 to 2,000 mg daily (extended-release preferred for GI tolerability) may be continued alongside retatrutide. The two agents act through complementary mechanisms: metformin suppresses hepatic glucose output via AMPK activation, while retatrutide reduces caloric intake and increases energy expenditure. No pharmacokinetic interaction data exist for this combination, but GLP-1 receptor agonists and metformin are routinely co-prescribed in type 2 diabetes without known interaction concerns. [13]

Spironolactone 25 to 100 mg daily for anti-androgenic effect may also be continued if already prescribed. Spironolactone does not interact with GLP-1-class agents pharmacokinetically, though both may lower blood pressure modestly, requiring monitoring. [14]

Adverse Effects to Anticipate in the PCOS Population

Gastrointestinal Events

In the phase 2 obesity trial, nausea occurred in 42 percent of participants at 8 mg and 45 percent at 12 mg during titration. Vomiting occurred in 22 percent and 24 percent respectively. These rates are higher than those reported for semaglutide 2.4 mg (nausea 44 percent, vomiting 24 percent at the highest dose in STEP-1), suggesting a similar GI burden. [5][6] Women with PCOS may have pre-existing GI motility differences; slower titration (6-week intervals instead of 4-week) is an option for patients with high GI sensitivity.

Thyroid C-Cell Signal

Rodent studies show GLP-1 receptor agonism increases thyroid C-cell proliferation, which is the basis for the boxed warning on all approved GLP-1 receptor agonists regarding medullary thyroid carcinoma risk. Retatrutide carries the same theoretical concern. Baseline calcitonin measurement is advisable, and the drug should not be used in patients with a history of thyroid carcinoma. [15]

Cardiovascular Effects

The phase 2 trial reported a mean heart rate increase of 4 to 6 beats per minute across active dose groups, consistent with the class effect of GLP-1 receptor agonism. No major adverse cardiovascular events were adjudicated in the 48-week trial, though this observation period is too short to draw conclusions about MACE outcomes. Women with PCOS already carry a twofold to threefold elevated cardiovascular risk compared to age-matched controls, per a 2023 systematic review in the Journal of the American Heart Association (N=22 studies, over 800,000 women). [16]

Reproductive Safety

No human teratogenicity data exist for retatrutide. GLP-1 receptor agonists as a class are categorized as potentially harmful in pregnancy because animal studies show fetal harm at doses producing maternal toxicity. Retatrutide's glucagon agonism adds an additional theoretical concern: glucagon stimulates glycogenolysis and may affect fetal glucose homeostasis during early organogenesis. Women of reproductive age must be counseled explicitly and should use barrier or hormonal contraception throughout treatment. [17]

How Retatrutide Compares to Approved PCOS Pharmacotherapy

No drug is FDA-approved specifically for PCOS as a composite disorder. Approved agents are used for individual features:

• Metformin: Reduces insulin resistance; modestly reduces androgen levels. HOMA-IR falls by a mean of 25 to 30 percent in PCOS trials. [18]
• Oral contraceptives: Reduce LH-driven androgen production; do not address insulin resistance and may worsen it at higher estrogen doses.
• Spironolactone 50 to 200 mg: Reduces hirsutism and acne by blocking androgen receptors; no effect on ovulation or metabolic markers.
• Clomiphene / letrozole: Ovulation induction only; no metabolic benefit.
• Semaglutide 2.4 mg (Wegovy): Off-label for PCOS but with a stronger evidence base. A 2023 trial by Cena et al. (N=40) showed semaglutide 1 mg weekly reduced total testosterone by 30 percent and restored menstrual regularity in 65 percent of participants over 24 weeks, published in Nutrients. [19]

Retatrutide's weight-loss magnitude exceeds semaglutide's in the head-to-head comparison from phase 2 data, which may translate to greater androgen reduction through fat-mass-dependent mechanisms. That premise has not been tested directly.

Patient Selection: Who May Be a Reasonable Candidate?

Not every woman with PCOS is an appropriate candidate for off-label retatrutide. A reasonable candidate profile, drawn from the mechanistic and tolerability data, includes:

• Age 18 to 45 years with confirmed PCOS by Rotterdam criteria
• BMI ≥27 kg/m² with at least one metabolic comorbidity
• Inadequate response to six or more months of optimized metformin plus lifestyle intervention
• No desire for immediate pregnancy (minimum 3-month washout recommended before attempting conception, consistent with the approach used for semaglutide) [20]
• No personal or family history of MEN2 or medullary thyroid carcinoma
• Ability to attend monthly monitoring visits for the first six months

Women whose primary goal is ovulation induction for fertility should exhaust FDA-reviewed options first, including letrozole (first-line per ACOG 2023 guidance) and gonadotropin therapy, before considering an investigational agent. [11]

Accessing Retatrutide Off-Label

Retatrutide is not commercially available through retail pharmacies in the United States. Patients seeking access typically approach one of three routes:

1. Clinical trial enrollment: The TRIUMPH phase 3 program is recruiting at multiple sites. Clinicaltrials.gov (NCT05584839 and related identifiers) lists open studies. Trial participation is the only route that guarantees pharmaceutical-grade retatrutide under regulatory oversight.
2. Compounding pharmacies: Some 503A and 503B compounders produce peptide preparations marketed as retatrutide. The FDA has not cleared these preparations. Purity and dose accuracy vary substantially across compounders. Clinicians prescribing these preparations assume significant liability.
3. International import: Not a recommended pathway given customs restrictions on unapproved drugs and complete absence of quality assurance.

The FDA's position on compounded GLP-1 and GIP/GLP-1 agents has grown more restrictive since 2024, and enforcement actions against compounders of semaglutide and tirzepatide set a precedent that may extend to retatrutide compounds. [9]